Navigation Links
ISTA Pharmaceuticals Announces Preliminary Results of T-Pred Studies
Date:9/8/2009

IRVINE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced preliminary results from two recently completed studies on its investigational ophthalmic product, T-Pred(TM) (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension). The Company is developing T-Pred as a treatment for inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial ocular infection exists, or there is a risk of bacterial infection.

In the first study, ISTA evaluated the antimicrobial equivalence between T-Pred and a tobramycin-containing reference product. In vitro tests were conducted to compare the kill rate of T-Pred with the kill rate of the reference product for each of the micro-organisms listed in the reference product's package insert as well as additional micro-organisms specified by the Food and Drug Administration (FDA). ISTA successfully demonstrated the antimicrobial bioequivalence of T-Pred to the reference product in each of the 26 required tests.

The second study was a Phase 3 clinical study designed to determine the bioequivalence of prednisolone concentrations between T-Pred and a reference product containing prednisolone acetate 1.0%. The multi-center, randomized, double-masked study enrolled 172 patients undergoing bilateral cataract removal. Patients served as their own internal control in this study, receiving one drop of either T-Pred or the prednisolone reference product prior to cataract extraction. Aqueous humor sampling was performed at one of four assigned time points. In order to demonstrate the bioequivalence of the two products, the ratio of calculated prednisolone values in aqueous humor needed to fall between 80% and 125%, with a 90% confidence interval for the rat
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
2. Vion Pharmaceuticals Announces Results of the Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)
3. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
4. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
5. NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting
6. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
7. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
8. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
9. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
10. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
11. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
(Date:7/11/2014)... 11, 2014 Neurelis, Inc. ("Neurelis") today announced ... the option held by Biotie to purchase Neurelis, clearing ... NRL-1 (intranasal diazepam) for pediatric and adult epilepsy patients ... past year, Biotie has advanced the development program for ... pivotal clinical work required for NDA submission to the ...
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... published in an upcoming issue of,Anti-Cancer Drugs , ... today announced that two peer-reviewed publications,will feature Protox's ... ("JNCI") has published the work conducted by Dr. ... in collaboration,with Protox scientists. The paper describes the ...
... 20, 2007--Researchers studying influenza,transmission patterns in the ... uncovered the unexpected finding that,each season influenza ... to the more populated centers. Their work, ... of the National Institutes,of Health (NIH), can ...
Cached Medicine Technology:Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases 2Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases 3Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 2Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 3
(Date:7/13/2014)... (PRWEB) July 14, 2014 Worldwide ladies ... selection. Angeldress.co.uk has taken a different approach and ... fresh items are offered in more colour choices that ... a famous brand of women’s special occasion apparels. The ... Its dress specialists are working hard to create the ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Ticket Down ... Real Madrid Tickets . For the fifth straight year ... Cup will be held at American stadiums this summer. The ... on American soil. The eight teams are split into two ... stage, the top two teams will compete to become champion. ...
(Date:7/13/2014)... inexpensive, portable, microchip-based test for diagnosing type-1 diabetes ... better understand the disease, according to the device,s ... , Described in a paper to be published ... the test employs nanotechnology to detect type-1 diabetes ... the two main forms of diabetes mellitus, which ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 The North American ... million in 2013 to $5,450 million by 2018, at a ... systems market is expanding at a rapid pace in North ... ever tightening laws on water & wastewater storage and collection, ... infrastructure. The market is expanding at a healthy rate in ...
(Date:7/13/2014)... 13, 2014 Fuel additives are chemicals, ... diesel, jet fuel, kerosene, and so on, in order ... for reducing the corrosion effects caused by fuels and ... to any fuel, provide economies of scale in the ... the overall cost of the fuel products. , The ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Announces Summer Sale For Pink And Red Bridesmaid Dresses; The Current Discount Is Up To 80% Off 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4
... more respectful, SAN DIEGO, March 19 Over one-third ... to three years, find a non-nursing,job, work part-time, or work ... AMN Healthcare, the largest health care staffing firm in,the country, ... baby,boomer nurses may be facing career burn-out. About 46 percent ...
... fast and precise ... ALTO, Calif., March 19 Varian Medical,Systems (NYSE: ... centers in North,America and Europe to further the development ... fast and precise,cancer treatments. RapidArc makes it possible to ...
... Names New President and CEO, MIAMI, March 19 ... (NPF) announced today that Joyce A.,Oberdorf has been named ... was most recently Vice President, Policy, Planning,and Communications at ... "Ms. Oberdorf is an outstanding choice to help NPF ...
... Johnson & Johnson Vision ... Contact Lenses, JACKSONVILLE, Fla., March 19 Johnson ... the ACUVUE(R) The Difference is,Real(TM) Trip to Beijing Sweepstakes, ... performance. The sweepstakes runs March 18,through April 11, 2008, ...
... China, March 19 /Xinhua-PRNewswire-FirstCall/ -- China,Nepstar Chain Drugstore Ltd. ... largest drugstore chain in China based on the number ... the,quarter and fiscal year ended December 31, 2007., ... December 31, 2007: -- Revenues increased 9.5% to ...
... Mustang at the New York, International Auto Show to raise money for breast ... ... Komen Race for the Cure - to $500 for ... more than $95 million in, cash and in-kind contributions for breast cancer education and ...
Cached Medicine News:Health News:Survey: 35% of Baby Boomer Nurses Plan a Career Change in the Next One to Three Years 2Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 2Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 3Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 4Health News:Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments 5Health News:National Parkinson Foundation Announces Its New President and CEO 2Health News:National Parkinson Foundation Announces Its New President and CEO 3Health News:Experience a Close-Up View of the Beijing 2008 Olympic Games 2Health News:Experience a Close-Up View of the Beijing 2008 Olympic Games 3Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 2Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 3Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 4Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 5Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 6Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 7Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 8Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 9Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 10Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 11Health News:China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007 12Health News:Ford Launches 'Warriors in Pink' Mustang for '09, Doubles Contributions To Race For The Cure 2
Zero clearance, front breathing, undercounter refrigeration system....
Designed to meet the requirements of reagent grade water for routine analysis....
... Basic Laboratory Needs, Synergy systems produce ultrapure water ... 1 to 1.2 L/min to meet the basic ... incorporates a dual-wavelength UV lamp (185 nm and ... of organic contaminants (< 5 ppb TOC when ...
... Compact System Produces Type I Water Directly from ... designed for scientists who need 5 to 15 ... not have easy access to acceptable quality pretreated ... 0.6 L/min of ultrapure (Type I) water on ...
Medicine Products: